The Future of
Life-saving Treatments
Vision & Mission
We create the future of life-saving treatments by aiming to reduce the organ shortage and speed up drug development by providing accessible life science solutions that combine biology and technology.
REPORT
Q1 2024
NOTICE
Annual General Meeting 2024
press releases
05/13/24RegulatoryBICO publishes adjusted Annual and Sustainability Report 2023
05/07/24RegulatoryPublication of BICO Group Interim report January-March 2024
05/06/24RegulatoryBICO changes method for impairment test of goodwill resulting in retroactive impairment of goodwill for 2022 and 2023 and provides preliminary figures for Q1 2024
04/16/24RegulatoryNotice to attend the Annual General Meeting in BICO Group AB (publ)
03/15/24RegulatoryFounders leave after eight years
03/15/24RegulatoryBICO Publishes Annual and Sustainability Report 2023
02/20/24RegulatoryPublication of BICO Group Year-end report 2023
02/14/24RegulatoryBICO announces goodwill impairment of SEK 582m and provides preliminary figures for Q4 2023
12/04/23RegulatoryBICO company Biosero has signed an agreement to develop laboratory automation solutions to a value of 28 MUSD
11/14/23RegulatoryPublication of BICO Group interim report July – September 2023
11/13/23BICO has divested Ginolis
11/09/23RegulatoryBICO Group AB Nomination Committee 2024 AGM appointed
11/01/23RegulatoryBICO releases preliminary revenue, EBITDA, and cash flow from operating activities for Q3, 2023
08/22/23RegulatoryPublication of BICO Group interim report April – June 2023
08/21/23RegulatoryBICO announces goodwill impairment predominantly due to increased WACC, and write-downs of assets
08/21/23RegulatoryMaria Forss is appointed new President and CEO of BICO Group AB (publ)
05/09/23RegulatoryBulletin from Annual General Meeting in BICO Group AB (publ)
05/04/23RegulatoryPublication of BICO Group interim report January – March 2023
04/04/23RegulatoryNotice to attend the Annual General Meeting in BICO Group AB (publ)
03/17/23RegulatoryBICO Publishes Annual Report and Sustainability Report 2022
02/27/23BICO introduces new life sciences manufacturing platform integrating ABB Robotics technology
02/22/23RegulatoryPublication of year-end Report January – December 2022
01/31/23RegulatoryBICO Group AB (publ) announces an increase in number of shares and votes
01/05/23RegulatoryBICO appoints COO
01/02/23RegulatoryBICO Group Appoints New CFO
12/30/22RegulatoryBICO Group AB (publ) announces an increase in number of shares and votes
12/14/22RegulatoryBulletin from Extraordinary General Meeting in BICO Group AB (publ)
12/08/22RegulatoryBICO agrees with Sartorius on strategic cooperation, followed by a SEK 487m directed share issue of shares to Sartorius
11/14/22RegulatoryNotice of extraordinary general meeting in BICO Group AB (publ)
11/10/22RegulatoryBICO Group announces new financial targets
Calendar
Say goodbye to
Animal Testing Manual Work Static Analysis
Automated Laboratory Workflows Through Bioconvergence
Learn how synergies between our technologies enable laboratories to develop new drugs faster and more cost efficient.
Bico by numbers
Products that Fuel Groundbreaking Scientific Discoveries
BICO News Feed
May 13, 2024
Cellenion Find us at Booth #138 at ASMS US – Anaheim, CA
Cellenion Find us at Booth #138 at ASMS US – Anaheim, CA
March 19, 2024
Scienion sciFLEXARRAYER User Training in Berlin
Scienion sciFLEXARRAYER User Training in Berlin
December 4, 2023
Cellink Stefan Blomsterberg appointed as new CEO of CELLINK Bioprinting AB
Cellink Stefan Blomsterberg appointed as new CEO of CELLINK Bioprinting AB
